A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Following Subcutaneous Injections of QGE031 in Japanese Atopic Male Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ligelizumab (Primary)
- Indications Hypersensitivity
- Focus Adverse reactions; Pharmacogenomic
- 16 May 2012 New trial record